Lab Report
Link to Evans Scientific Report 2008 185.61 Kb
Key Publications
Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TRJ, de Bono JS (2008). A phase I, pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat (PXD101) in patients with advanced solid tumors. Clin Cancer Res. 14, 804-10.
Evans TRJ, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M,
Leonard RCF, Mansi JL (2005). A phase III randomised trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy of women with breast cancer: An Anglo-Celtic Co-operative Oncology Group Study. J Clin Oncol. 23, 2988-95.
Evans TRJ, Di Salle E, Ornati G, Lassus M, Strolin Benedetti M, Pianezzola E, Coombes RC (1992). A phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor in postmenopausal women. Cancer Res. 52, 5933-9.
Biography
Education and qualifications
2000: FRCP (London)
1998: FRCP (Glasgow)
1993: MD, University of London
1988: MRCP (UK)
1984: MB BS, St Bartholomew’s Hospital, University of London
Appointments
2005-present: Professor of Translational Cancer Research (University of Glasgow); Honorary Consultant Medical Oncology (Beatson West of Scotland Cancer Centre, Glasgow)
2007-present: Deputy Head of Division, Division of Cancer Sciences & Molecular Pathology, University of Glasgow
2007-present: Honorary Group Leader, Beatson Institute for Cancer Research
1996-2005: Senior Lecturer and Honorary Consultant in Medical Oncology, Centre for Oncology & Applied Pharmacology, University of Glasgow; Beatson Oncology Centre, Glasgow
1991-1966: Lecturer/Honorary Senior Registrar in Medical Oncology, St George’s Hospital Medical School, London
1989-1991: Research Fellow in Medical Oncology, St George’s Hospital Medical School and Charing Cross Hospital Medical School, University of London; Institute of Cancer Research, Sutton, Surrey
Committee membership
2007-present: Institute of Cancer Research Clinical Trials and Statistics Unit Breast Systemic Therapies Steering Committee
2007-present: JCHMT Innovative Medical Oncology Curriculum and Assessment – Site Specific Group Co-Leader, Basic Science of Oncology
2007-present: NCRI Upper GI Cancer Clinical Studies Group
2007-present: Cancer Research UK New Agents Committee
2007-present: Editorial Board, The Open Clinical Cancer Journal
2006-present: Scholarship Committee, The Royal College of Surgeons and Physicians of Glasgow
2006-present: Scientific Advisory Committee, Association of International Cancer Research
2006 – 2008: Feasibility Studies Committee, Cancer Research UK
2005 – 2009: MCRP (UK) Part II Examination Board
2005-present: Editorial Board, British Journal of Cancer
2004-present: Faculty 1000 Oncology Evaluation Board, Oncology Agents Section
Recent Publications
Scott LC,Yao JC, Benson AB, 3rd,Thomas AL, Falk S, Mena RR, Picus J,Wright J, Mulcahy MF, Ajani JA, Evans TRJ (2009). A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemotherapy & Pharmacology 63, 363-70.
Graham JS, Falk S, Samuel LM, Cendros JM, Evans TRJ (2009). A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy. Cancer Chemotherapy & Pharmacology 63, 945-52.
Morton JP, Klimstra DS, Mongeau ME, Lewis BC (2008). Trp53 deletion stimulates the formation of metastatic pancreatic tumors. Am J Path. 172, 1081-7.
Plummer R, Jones R, Middleton M,Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnston P, Steinfeldt H, Dewji R,Wang D, Robson L, Calvert H (2008). Phase I study of the poly(ADP-Ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumours. Clin Cancer Res. 23, 7917-23.
Sarker D, Molife R, Evans TRJ, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S,Aziz N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, de Bono JS (2008). A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res. 14, 2075-81.
Steele NL, Plumb JA,Vidal L,Tjornelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TRJ, DeBono JS (2008). A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 14, 804-10.
Evans J, Chitnis MM,Talbot DC (2008). Principles of chemotherapy and drug development. In P. Price, K. Sikora and T. Illidge, ed. Treatment of cancer. London: Hodder Arnold 2008; 75-111
Koutras AK, Mastronikolis NS, Evans TRJ, Papadeas ES, Makatsoris T, Kalofonos HP. Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer. Acta Oncologica 47, 1171-73.
Koutras AK, Evans TRJ (2008). The epidermal growth factor receptor family in breast cancer. Onco Targets & Therapy 1, 5-19.
Oien KA, Evans TRJ (2008). Raising the profile of cancer of unknown primary. J Clin Oncol. 26, 4373-75.
Roxburgh P, Evans TRJ (2008). Systemic therapy of hepatocellular carcinoma: Are we making progress? Advances in Therapy 25, 1089-104.
Holmes WM, Maclellan S, Condon B, Dufes C, Evans TRJ, Uchegbu IF, Schätzlein AG (2008). High-resolution 3D isotropic MR imaging of mouse flank tumours obtained in vivo with solenoid RF micro-coil. Physics in Medicine & Biology 53, 505-13.
Jones RJ, Hawkins RE, Eatock MM, Ferry DR, Eskens FA, Wilke H, Evans TRJ (2008). A phase II open label study of DHApaclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemotherapy & Pharmacology 61, 435-41.
Lindsay CR, Evans TRJ (2008). Targeting insulin growth factor receptors: a potential novel anti-cancer therapy. Biologics: Targets & Therapy 2, 855-64.
Guo X, Evans TRJ, Somanath S, Armesilla AL, Darling JL, Schätzlein A, Cassidy J, Wang W (2007). In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines. BJC 97, 745-54.
Macpherson IRJ, Jones RJ, Evans TRJ (2007). Clinical development of Src family kinase inhibitors in malignant melanoma. The Open Cancer J. 1, 9-20.
Øien KA, Dennis JL, Evans TRJ (2007). Metastatic adenocarcinoma of unknown origin. In N. Kirkham and N. A. Shepherd, ed. Progress in Pathology. Cambridge: Cambridge University Press; 135-62.
Øien KA, Stewart I, Evans TRJ (2007). Unknown primary. In M. R. Alison, ed. The Cancer Handbook. Chichester: John Wiley and Son; Chapter 61.
Current strategies in the development of new therapies for malignant disease are based on exploiting our increasing understanding of the molecular basis of cancer. 
